Table 2.
Association between NUDT15 variants and the early neutropenia, the median 6-MP dose of patients with ALL on maintenance therapy
| Characteristics | The intermediate metabolizer group, n = 25 | The normal metabolizer group, n = 77 | OR (95% CI) | p value |
|---|---|---|---|---|
| Age (year) | 6 (2–11)a | 6 (2–14)a | - | 0.8 |
| Sex (%) | 0.7 (0.3–1.9) | 0.53 | ||
| Female | 36.7 | 38.9 | - | - |
| Male | 63.3 | 61.1 | - | - |
| Leukemia type, risk group (%) | 0.85 | |||
| B-ALL standard risk | 50 | 48.3 | - | - |
| B-ALL high risk | 38.9 | 41.7 | - | - |
| T-ALL | 11.1 | 10 | - | - |
| Severe neutropenia, n (%) | ||||
| 1 month | 9 (36) | 8 (10.4) | 4.9 (1.6–14) | 0.003 |
| 2 months | 15 (60) | 13 (16.9) | 7.4 (1.2–20) | 0.0001 |
| 3 months | 17 (68) | 14 (18.2) | 10 (3.4–26) | 0.0001 |
| Febrile neutropenia, n (%) | 10 (40) | 8 (10.4) | 5.7 (1.9–17) | 0.003 |
| Median 6-MP dose (mg/m2/day)a | ||||
| First month | 67 | 68.5 | – | 0.23 |
| Second month | 55 | 66.7 | – | 0.0001 |
| Third month | 47.6 | 65.9 | – | 0.0001 |
| Median 6-MP adjusted dose (mg/m2/day) + | 48.7 | 64.3 | – | 0.0001 |
OR, odds ratio; 95% CI, 95% confidence interval. p values were calculated using the Mann-Whitney U-test. The statistical significance of p < 0.05.
a
Median (interquartile range).